$1.4b in sales

Rockland-based biotech EMD Serono, the North American arm of Germany’s Merck KGaA, reported revenue of $1.4 billion last year, mainly from sales of four drugs:

¦ Rebif, for multiple sclerosis

¦ Gonal-F, for infertility

¦ Saizen, for growth hormone deficiency

¦ Serostim, for boosting HIV patients’ body weights

The main product in its pipeline of new drugs not yet approved is ­Avelumab, which targets a rare skin cancer, Merkel cell carcinoma. It is also being tested as a treatment for ovarian, bladder, gastric, and lung cancers.

SOURCE: EMD Serono